Diabetic Neuropathy Market Size, Share and Trends 2025 to 2034

Diabetic Neuropathy Market Size and Forecast 2025 to 2034

The global diabetic neuropathy market size was calculated at USD 4.50 billion in 2024 and is predicted to reach around USD 9.06 billion by 2034, expanding at a CAGR of 7.24% from 2025 to 2034. The increasing prevalence of diabetic neuropathy in geriatric patients already affected by diabetes and further innovations in the development of novel drugs in the treatment of conditions drive the growth of the market.

Diabetic Neuropathy Market Key Takeaways

• North America dominated the global diabetic neuropathy market with the largest market share of 38% in 2024.
• Asia Pacific is expecting substantial growth in the market during the predicted period.
• By disease type, the peripheral segment has held a major market share of 63% in 2024.
• By disease type, the autonomic segment will show notable growth in the market during the forecast period.
• By drug type, the non-steroidal anti-inflammatory drugs segment dominated the market in 2024.
• By drug type, the opioid segment expects substantial growth in the market during the predicted period.
• By distribution channel, the hospital pharmacies will witness substantial growth during the predicted period.

How Can Artificial Intelligence (AI) Impact the Diabetic Neuropathy Market?

The implementation of artificial intelligence into the diabetic neuropathy market is one of the fastest-growing applications and technologies for improving efficiency and efficiency. In the case of diabetic neuropathy, the type 2 diabetic has an 8-45% chance of having the neuropathy conditions. AI helps filter the patients who have a greater risk of diabetic neuropathy. With the diagnosis, AI can also provide different treatment strategies for the treatment or management of diabetes. AI helps in improving the treatment and management of diabetes neuropathy with reduced medical costs and better patient outcomes. 

• In September 2024, Nevro Corp., a leading medical devices firm globally, announced the launch of HFX AdaptivAI™, an AI-driven technology aiming for the treatment of chronic pain, approved by the U.S. Food and Drug Administration (FDA). It is the personalized management platform powered by HFX iQ for the spinal cord stimulation (SCS) system.

U.S. Diabetic Neuropathy Market Size and Growth 2025 to 2034

The U.S. diabetic neuropathy market size was exhibited at USD 1.28 billion in 2024 and is projected to be worth around USD 2.62 billion by 2034, growing at a CAGR of 7.42% from 2025 to 2034.

North America dominated the global diabetic neuropathy market in 2024. The growth of the market is attributed to the rising prevalence of lifestyle diseases such as high blood pressure, diabetes, and others due to the changing lifestyle preferences, acceptance of sedentary lifestyle, eating habits, increasing consumption of sugar, higher consumption of alcohol and smoking which is the major cause of diabetes that boosts the cases of diabetic neuropathy. 

Additionally, the rising healthcare infrastructure in regional countries like the United States and Canada, which is the availability of skilled healthcare professionals and technological advancements in medical devices for the treatment of several diseases, including diabetic neuropathy, is contributing to the expansion of the diabetic neuropathy market in the region. 

• During the period of August 2021–August 2023, the total prevalence of diabetes was 15.8%, in which there is 11.3% are diagnosed and 4.5% are undiagnosed in the U.S. adults. 
• The prevalence of diabetes between the ages of 20-a20 and 39 increased by 3.6% in adults ages, and between the ages of 40 and 59 increased by 17.7%, and 27.3% for those 60 and above.

The Asia Pacific is expecting substantial growth in the diabetic neuropathy market during the predicted period. The rising cases of diabetic neuropathy cases in regional countries such as China, India, and Japan, owing to the presence of a large number of geriatric populations with diabetes, are driving the demand for treatment for diabetic neuropathy and other diabetes-related disease. The growing healthcare and pharmaceutical infrastructure in the regional countries, with the ongoing investment and initiatives in healthcare development, boosts the efficiency in the treatment of several chronic diseases. 

The increasing research and development program in diabetes treatment contributes to the growth of the diabetic neuropathy market across the region. India is one of the leading prevalent countries in the world in terms of the rising number of diabetic people. According to the Indian Council of Medical Research, the prevalence of diabetes in India will be 10.1 crores in 2023. While China has one of the largest numbers of people with diabetes there are 118 million people are affected by diabetes, which is approximately 22% of the global diabetic population. 

Market Overview 

Diabetic neuropathy is a health issue related to diabetes that can lead to nerve damage throughout the body. Diabetes can affect the nerves of the body, leading to dysfunction in movement and sensation. Several leading factors are the major cause of diabetic neuropathy, such as high blood sugar (glucose), metabolic factors, and inherited factors. The neuropathy condition occurs within 10 years after the diagnosis of diabetes. Diabetic mononeuropathy, diabetic polyneuropathy, diabetic autonomic neuropathy, and proximal neuropathy (diabetic amyotrophy) are some types of diabetic neuropathy. The increasing cases of diabetes in the population globally accelerate the cases of diabetic neuropathy and the diabetic neuropathy market. 

Diabetic Neuropathy Market Growth Factors

• Rise in an aging population: The rising cases of the geriatric population in the world, which are more prone to chronic diseases such as high blood pressure, diabetes, and cardiovascular disease, which expect higher chances of diabetic neuropathy. 
• Healthcare infrastructure: The increasing healthcare in developing and developed economies drives advancements in the medication and treatment of several chronic diseases, such as diabetes, and other related health issues, such as diabetes neuropathy. 
• Increasing lifestyle changes: changing lifestyle preferences due to urbanization, economic development, sleeping and eating habits, and rising smoking and alcohol consumption, which are the major causes of diabetes and nerve damage due to high diabetes, boost the demand for the diabetic neuropathy market. 

Market Scope

Market Dynamics

Drivers

Increasing diabetes cases

The increasing prevalence of diabetes patients in the world is due to the increasing presence of the geriatric population, changing lifestyles, habitat, genetics, and several other factors that are anticipated to increase the chance of nerve damage, which drives diabetic neuropathy cases in diabetic patients. An increasing number of patients with diabetes have diabetic neuropathy conditions with the symptoms of numbness in the different body parts. The rising economic development in various countries drives the per capita income, which leads to lifestyle changes and consumption of smoking and alcohol, which is the leading factor that contributes to the growing number of diabetes cases in adults. 

Restraint

High cost 

The increased cost of formulation and development of drugs for the treatment of diabetic neuropathy and the availability of alternative treatments with better patient outcomes are restraining the growth of the diabetic neuropathy market.

Opportunity

Advancements in the treatment of diabetic neuropathy 

The increasing investment in research and development activities in the further expansion and launch of new advancements in the medication and treatment of diabetes and related health issues, such as diabetic neuropathy for the early detection for preventing it from spreading complications and timely intervention drives the potential growth in the diabetic neuropathy market. Leading pharmaceutical companies are investing in the development of diabetes neuropathy management solutions. 

Disease Type Insights

The peripheral segment led the global diabetic neuropathy market in 2024. The increasing prevalence of diabetes in the population due to the aging population, changing lifestyle, and genetics drives. Peripheral neuropathy is a type of diabetic neuropathy; it is the damaged nerve that is used to affect legs, feet, hands, and arms sometimes. In the case of peripheral neuropathy includes symptoms like pickling, numbness, or tingling on hands and feet, sensitivity, muscle weakness, inability to move motor nerves, and others. It can be treated by different diagnostic methods, therapies, and medicines.

The autonomic segment has notable growth in the market during the forecast period. The increasing cases of autonomic neuropathy are due to the increasing cases of diabetes in the population. Autonomic neuropathy damages the nerve that is responsible for automatic body functions. Body temperature, blood pressure, heart rate, urination, digestion, and bowel movement are the major functions that are affected by autonomic neuropathy.  

Drug Type Insights

The non-steroidal anti-inflammatory drugs segment dominated the diabetic neuropathy market in 2024. The non-steroidal anti-inflammatory drugs are widely accepted for the treatment of diabetic neuropathy due to their effectiveness in neuropathy dysfunction. It helps in reducing and managing pain and is mostly prescribed by doctors as the first line of treatment for neuropathy dysfunction. Non-steroidal anti-inflammatory drugs restrict the production of prostaglandins, which reduce peripheral and central sensory hypersensitivity and cause inflammation associated with nerve injury. The increasing investment in the development of diabetic neuropathy drug types is driving the growth of the non-steroidal anti-inflammatory drugs segment. 

The opioid segment expects substantial growth in the market during the predicted period. The opioid is used in the management of chronic neuropathic pain and is prescribed as the second or third line of treatment for the reduction and management of diabetic neuropathy. The increasing prevalence of diabetic neuropathy in the population boosts the demand for efficient drugs or treatment types. 

Distribution Channel Insights

The hospital pharmacies will witness substantial growth during the predicted period. The rising acceptance of the hospital pharmacies for the medication for diabetic neuropathy. The increasing rate of hospitalization for diabetic neuropathy for the management and treatment due to the higher availability of skilled professionals and technologically advanced medical devices that help in effective diagnostics and treatment of the disease. 

Diabetic Neuropathy Market Companies

• Abbott
• Eli Lilly and Company
• Pfizer. Inc
• Janssen Pharmaceuticals, Inc
• Lupin Pharmaceuticals
• Astellas Pharma Inc
• Glenmark Pharmaceuticals Ltd
• Boehringer Ingelheim GmbH
• Novartis

Latest Announcement by Industry Leaders

• In November 2024, Abbott opened a new manufacturing facility to meet the demand for diabetes technology. The facility aims to produce the highest number of FreeStyle Libre sensors and the latest production of a world-leading line of continuous glucose monitoring (CGM) systems for diabetic people. 
• In June 2023, Pfizer Inc. announced the continuation in the decision for the progression of Pfizer Inc. one oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate for the clinical development for the potential treatment of obesity patients and Type 2 diabetes mellitus (T2DM). 

Recent Developments

• In March 2024, Procter & Gamble (P&G) Health, with Obesity International, collectively launched "Language of Diabetes," the latest patient empowerment and awareness tool. The technology-based platform was designed to lower the diabetes complications incidence in India, where 236 million people are affected by diabetes and pre-diabetes. 
• In August 2024, Sheffield Teaching Hospitals NHS Foundation Trust launched the smart tech initiative for minimizing the risk of nerve damage in people who are affected with type 2 diabetes. The smart technology is used to track body fat and glucose levels in the participants in real time. 

Segments Covered in the Report 

Disease Type Insights

• Peripheral 
• Autonomic 
• Proximal 
• Focal 

Drug Type Insights

• Non-steroidal anti-inflammatory Drugs
• Opioid
• Anti-Seizure
• Antidepressants

Distribution Channel Insights

• Hospitals Pharmacies
• Retail Pharmacies and Stores
• Other

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa